Atherosclerotic cardiovascular disease Cardiovascular disease
Conditions
Interventions
The volunteer will be given ziltivekimab as an injection under the skin
(subcutaneous) of the abdomen.
There are 3 different study treatments in this study. The volunteer will
receive 1 of them. W
Sponsors
Novo Nordisk A/S
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Male or female - Aged 18-64 years (both inclusive) at the time of signing informed consent. - Body mass index (BMI) between 18.5 and 29.9 kg/m2 (both inclusive). - Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion criteria
Exclusion criteria: - Known or suspected hypersensitivity to study intervention(s) or related products. - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method, as defined in section 10.4. - Any disorder which in the investigator*s opinion might jeopardise participant*s safety or compliance with the protocol. - Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medication, highly effective contraceptives and occasional use of paracetamol, acetylsalicylic acid within 14 days before trial product administration. - Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the pharmacokinetic properties of a single s.c. administration of ziltivekimab in formulation B for the manual syringe, formulation D for the manual syringe, and formulation C for the pen-injector | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the pharmacokinetic properties of a single s.c. administration of ziltivekimab in formulation B for the manual syringe, formulation D for the manual syringe, and formulation C for the pen-injector, 50 days following dosing | — |
Countries
Netherlands
Outcome results
None listed